Molnupiravir, a new antiviral medicine approved by the World Health Organization on Thursday, will treat the Omicron variant of Coronavirus. It is the first oral antiviral medication to be incorporated into the COVID-19 treatment guidelines. Besides approving casirivimab-imdevimab for treatment of Omicron-infected patients, the body further recommended that it not be used for this infection. As part of its ninth update on COVID-19 therapeutics, the WHO released new treatment guidelines on its website on Thursday. The update read, “Because of these concerns and data gaps, molnupiravir should be provided only to non-severe COVID-19 patients with the highest risk of hospitalization. These are typically people who have not received a COVID-19 vaccination, older people, people with immunodeficiencies, and people living with chronic diseases”.